research P368 Rare skin disorders in IBD patients treated with anti-TNFs
Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.
Search
for
Sort by
Research
960-990 / 1000+ results 
research 264 CCR5 blockade shows prevention of alopecia areata development as well as improvement of alopecia areata
Blocking CCR5 can prevent and improve hair loss in alopecia areata.
research Response to ustekinumab in three pediatric patients with alopecia areata
Ustekinumab helped three kids with alopecia areata regrow hair.
research Gut instinct: Using tofacitinib to treat alopecia areata in the context of comorbid inflammatory bowel disease
Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.
research Ablative 2940 nm Er: YAG fractional laser for male androgenetic alopecia
research Primary Cutaneous Rhabdoid Squamous Cell Carcinoma: A Case Report and Review of Molecular Features
Recognizing RSCC is crucial due to its aggressive nature and high risk of poor outcomes.
research Adalimumab improves health-related quality of life (HRQoL) in patients with moderate to severe hidradenitis suppurativa (HS): Results from the first 12 weeks of PIONEER II
Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.
research Chemotherapy-Induced Alopecia
Imuvert can prevent some chemotherapy-induced hair loss.
research Dupilumab Associated Progression of Alopecia Areata to Alopecia Universalis: A Case Report
Dupilumab may worsen hair loss in patients with alopecia areata.
research Case Report: Baricitinib improved alopecia areata in a pediatric patient with atopic dermatitis
Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
research Therapy of Acute Myeloid Leukemia
Treating acute myeloid leukemia is challenging, especially in older adults, despite some advancements.
research Cytokine-targeted treatment in alopecia areata - new possibilities?
New cytokine-targeted therapies show promise for treating alopecia areata.
research An urticarial drug eruption caused by tofacitinib for alopecia universalis
A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
research Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series
Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
research Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series
Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
research Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
research In vivo reflectance confocal microscopic findings in a case of trichofolliculoma
Reflectance confocal microscopy may help diagnose trichofolliculoma by showing specific skin features.
research Human regulatory γδT lymphocytes as novel autoimmunity-protective cells: Lessons from alopecia areata
γδTregs may help treat autoimmune diseases like alopecia areata by promoting hair regrowth and reducing immune attacks.
research Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor
A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
research Low Level Laser versus Platelet-rich Plasma in Treatment of Alopecia Areata: A Randomized Controlled Intra-patient Comparative Study
Both platelet-rich plasma and low-level laser therapy effectively treat hair loss with minimal side effects and good cost-benefit ratio.
research FOCAL HYPERTRICHOSIS DURING TOPICAL TACROLIMUS THERAPY FOR CHILDHOOD VITILIGO
An 8-year-old girl with vitiligo developed extra hair growth on her knee after using tacrolimus ointment.
research Safety and efficacy of low-dose metronomic cyclophosphamide plus vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
The treatment is safe and shows promise for metastatic breast cancer.
research Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata
Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
research Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study
Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.
research Comparative evaluation of the efficacy of topical tacrolimus 0.03% and topical calcipotriol 0.005% mixed with betamethasone dipropionate versus topical clobetasol 0.05% in treatment of alopecia areata: A clinical and trichoscopic study
The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.
research Efficacy and safety of microneedling and oral tranexamic acid in the treatment of facial melasma in women: An open, evaluator-blinded, randomized clinical trial
Microneedling and oral tranexamic acid both improve facial melasma, but microneedling shows more sustained benefits.
research Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
Blocking IL-8 can reduce skin rashes from cancer treatment.
research Topical Treatment of Extended Alopecia
Ultraviolet light helped hair growth more effectively than triamcinolone acetonide.
research 415 IL-17C: Checkpoint in innate skin immunology
IL-17C is important in inflammatory skin diseases and could be a target for treatment.
research Weekly docetaxel in minimally pretreated cancer patients: A dose-escalation study focused on feasibility and cumulative toxicity of long-term administration
Giving docetaxel weekly at 40 mg/m² is manageable and has low toxicity for cancer patients.